Skip to main content

Table 4 Pathological and oncological results in trials using presurgical docetaxel ± hormonal therapy

From: Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

Therapy Docetaxel + Hormonal Therapy Docetaxel – Single Treatment
Author year Current series Narita 2012 Kim 2011 Mellado 2009 Sella 2008 Chi 2008 Prayer-Galetti 2007 Hussain 2003 Magi-Galuzzi 2007 Febbo 2005 Dreicer 2004
Patients (n) 30 18 24 RP/Rad 57 22 72 22 21 29 19 29
Docetaxel (D) Regime 3 cycles, q21, (75 mg/m2) 6 weeks, q7, (30 mg/m2) 3 cycles, q7 (3xD +1 week rest) (36 mg/m2) 3 cycles, q7 (3xD +1 week rest) (36 mg/m2) 4 cycles, q21 (70 mg/m2) 3 cycles, q7 (6xD +2 weeks rest) (35 mg/m2) 4 cycles, q21, (70 mg/m2) 6 cycles, q21 (70 mg/m2) 6 weeks, q7, (40 mg/m2) 6 months, q7, (36 mg/m2) 6 weeks, q7, (40 mg/m2)
LHRH Analog buserelin 9.45 mg (1x3 months) leuprorelin 11.25 mg (2x3 months) n.d. goserelin 10.8 mg (1x3 months) goserelin 3.6 mg (3x1 month) buserelin 6.6 mg (3x2 months) triptorelin 3.75 mg (4–12 months) n.d. n.d. n.d. n.d.
Antiandrogens bicaluta-mide 50 mg/d (9 weeks) bicaluta-mide 81 mg/d (12 weeks) n.d. flutamide 750 mg/d (12 weeks) bicaluta-mide 50 mg/d (12 weeks) flutamide 750 mg/d // bicaluta-mide 50 mg/d (4 weeks) n.d. n.d. n.d. n.d. n.d.
Estramustine n.d. 1120 mg/d (6 weeks) 420 mg/d for 3d n.d. 840 mg/d for 5d n.d. 600 mg/m2 (12 weeks) 840 mg/d for 3d n.d. n.d. n.d.
Therapy-weeks 9 6 12 12 12 24 16-60 18 6 24 6
pCR (%) 0 11.1 0 6 0 3.1 5 0 0 0 0
pMRD (%) 3.33 n.d. n.d. 6 n.d. 25 31.6* n.d. n.d. n.d. 7.14
iPSA, median, range (ng/ml) 25.8 25.8 22.3 9.7 21.2 10.8 41 16.1 n.d. n.d. 12
2.1-293 5.1-45.1 0.3-255 0.6-90.8 3.2-71.6 1.6-65.6 n.d. 2.4-175 2.5-43.3
iGl. sc. ≥7 (%) 90 87.4 100 95 n.d. 91 86 96 93 75 94
≥cT3 (%) 93.3 43.8 27 28 64 39 86 25 17.8 16 27
≥pT3 (%) 56.5 38.9 72.7 37 36.4 44 42 70 82.1 62 89
SVI (%) 53.3 11.1 45.5 n.d. 40.9 22 37 60 39.3 50 32
R0 (%) 66.7 100 63.6 64.7 72.7 73 74 70 75 n.d. 96
pN1 (%) 36.7 22.2 n.d. 3.9 18.1 6 21 10 14.3 0 14
FU, median, range (months) 48.6 18 24 35 23.6 42.7 53 13.1 49.5 26.5 23
20-88 1-49 n.d. 23-47 12-55 26-66 30-64 9-18 23-72 4.5-40 1.5-36
Recur. Pts. (%) 55.2 22.2 55 35.1 45.4 30.0 58.0 29.0 57.0 63.2 29.0
  1. Abbreviations: CSOS, cancer specific overall survival; cT3, clinical stage T3 with capsular penetration; pT3, pathological stage T3 with capsular penetration; D, docetaxel; FU, follow up; iGl. sc., initial Gleason score; iPSA, initial prostate-specific antigen; LHRH, luteinizing hormone releasing hormone; n.a., not applicable; n.d., not done; pN1, pathological lymph node involvement; pCR, pathological complete response; pMRD, pathological minimal residual disease with <5% PC in surgical specimens; *, pMRD with <10% PC in surgical specimens; q, treatment interval of 7 or 21 days; R0, negative surgical resection margin; RP, radical prostatectomy; Recur. Pts., patients with recurrent PC; RP/Rad, 12 patients treated with RP and 10 with external beam radiation; SVI, seminal vesicle invasion.